12-week biomarker data to be highlighted at the International Society of Frontotemporal Dementias (ISFTD) Annual Meeting

nfvPPA, the type of frontotemporal dementia (FTD) most commonly associated with tau pathology, currently has no approved treatments in the United States or European Union

BOSTON, Sept. 10, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders, today announced that neflamapimod, an oral, small molecule, drug candidate targeting critical disease processes underlying degenerative disorders of the brain, will be featured in a late-breaking oral presentation at the International Society of Frontotemporal Dementias (ISFTD) Annual Meeting in Philadelphia, Pennsylvania, taking place October 8-11, 2026.

CervoMed recently completed enrollment in the Phase 2a clinical trial of neflamapimod for the treatment of nonfluent variant primary progressive aphasia (nfvPPA). The presentation at the ISFTD conference, which was accepted based on an abstract describing 12-week biomarker data from the trial’s first eight participants, will highlight initial results for two plasma biomarkers, neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP), from at least 22 study participants.

The trial was designed to evaluate the safety, pharmacokinetics, and clinical effects of neflamapimod in participants with nfvPPA. The trial enrolled 25 participants and is being conducted at leading academic medical centers in the United States (U.S.) and United Kingdom (U.K.).